Can Certara's (CERT) New Compliance Platform Reinforce Its Regulatory Software Leadership?

• Earlier this month, Certara announced the launch of Pinnacle 21 Enterprise Plus, a new software platform designed to streamline the creation, reuse, and management of study data specifications required for regulatory submissions in clinical trials.
• This release directly targets common pain points in pharmaceutical data management by promising workflow improvements, enhanced compliance, and faster regulatory submissions for clinical and statistical programming teams.
• We'll now consider how this advanced compliance solution could influence Certara’s investment narrative, particularly around its regulatory software leadership.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Certara Investment Narrative Recap

Certara’s investment case centers on being at the forefront of regulatory software for biopharma, where workflow speed and data compliance drive value. The launch of Pinnacle 21 Enterprise Plus reinforces its software leadership and supports the company’s key short-term catalyst of expanding SaaS adoption, though it does not materially reduce the biggest risk: slow, complex pharma uptake and budget caution among Tier 1 customers, which still weighs on near-term revenue growth.

The most relevant recent development is the European Medicines Agency’s qualification of Certara’s Simcyp Simulator, which, like Pinnacle 21, accelerates submission timelines for pharmaceutical clients. Both announcements highlight Certara’s commitment to solutions that aim to ease regulatory hurdles, a central theme underpinning its growth catalysts and relevance in global drug development workflows.

But even with Certara’s upgraded platforms, investors should be aware that the biggest hurdle may still be customer caution and...

Read the full narrative on Certara (it's free!)

Certara's narrative projects $519.5 million revenue and $7.4 million earnings by 2028. This requires 8.6% yearly revenue growth and a $0.6 million decrease in earnings from $8.0 million currently.

Uncover how Certara's forecasts yield a $14.11 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members set fair value estimates for Certara from US$11.20 to US$14.11, across two contrasting views. With many pharma customers still piloting new platform use, investors should be aware of how adoption pace affects future growth and profitability forecasts.

Explore 2 other fair value estimates on Certara - why the stock might be worth as much as 22% more than the current price!

Build Your Own Certara Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Certara research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Certara research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Certara's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com